Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd (TLSA) Stock Ticker

NASDAQ: TLSA · Healthcare · Biotechnology
$1.01-2.88%
USD · as of 2026-09-27 · market cap $64.3M
Open TLSA in TickrDownload for iPhone

TLSA right now

Options price it to move more than 9 in 10 stocks.
Options expect by Oct 6±22.7%
Options expect by Oct 29±47.0%
IV rank (30-day)59% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full TLSA picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on TLSA
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.

TLSA stock facts

Ticker symbolTLSA
ExchangeNASDAQ Global Market
SectorHealthcare
IndustryBiotechnology
Market cap$64.3M
CEOIvor R. Elrifi
Employees10
HeadquartersLondon, GB
IPO date2018-11-20
Websitewww.tizianalifesciences.com

What you can see for TLSA on Tickr

Live TLSA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TLSA report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Tiziana Life Sciences Ltd?

The ticker symbol for Tiziana Life Sciences Ltd is TLSA, listed on the NASDAQ Global Market.

What is TLSA?

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative…

HomeExploreMarketLists
All pages